Evidence map›Paper›PMID 41229882›Full record

ArticleJournal of circulating biomarkers

Transcriptome biomarkers of colon cancer liver metastasis response to neoadjuvant triplet chemotherapy: a case series.

Nataliya Babyshkina, Tatyana Dronova, Dmitry Eremin, Alexey Dobrodeev, Dmitry Kostromitskiy, Sergey Vtorushin, Polina Gervas, Sergey Afanasiev, Nadejda Cherdyntseva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nataliya BabyshkinaDepartment of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.ORCID https://orcid.org/0000-0002-0562-3878
Tatyana DronovaDepartment of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Dmitry EreminDepartment of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Alexey DobrodeevDepartment of Abdominal Oncology, Cancer Research Institute - Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Dmitry KostromitskiyDepartment of Abdominal Oncology, Cancer Research Institute - Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Sergey VtorushinDepartment of General and Molecular Pathology, Cancer Research Institute - Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Polina GervasDepartment of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Sergey AfanasievDepartment of Abdominal Oncology, Cancer Research Institute - Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.
Nadejda CherdyntsevaDepartment of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) may be considered an effective option in the neoadjuvant setting for metastatic colon cancer (mCRC). To investigate potential molecular criteria for treatment response, we evaluate the transcriptome of paired primary colon tumors and liver metastases. Method: Two sets of quadruple-matched specimens (primary colon tumor, liver metastasis, normal colon and liver tissues) from five patients with resectable mCRC before and after neoadjuvant FOLFOXIRI were selected for RNA sequencing (RNA-seq). Results: RNA-seq data showed that liver metastases exhibited a higher number of differentially expressed genes (DEGs) than colon tumors (FDR < 0.05, 301 vs. 62, respectively). Up-regulation of Conclusion: Data obtained indicate transcriptional discordance between the primary tumors and liver metastases during neoadjuvant FOLFOXIRI, with the pattern of DEGs involved in their response being distinct. The EPS8L2 transcript could be regarded as a candidate biomarker of liver complete response; however, prognostic conclusions cannot be drawn from this cohort.

Indexed as

Colon cancer liver metastasisMetastatic colon cancerNeoadjuvant FOLFOXIRIRNA-seqTranscriptome biomarkers

Identifiers

PMID41229882
PMCPMC12603631

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.